

Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK-Inhibitor-Naive *ALK*+ Non-Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study

Myung J. Ahn,¹ Hye R. Kim,² James C.H. Yang,³ Ji-Yu Han,⁴ Jacky Yu-Chung. Li,⁵ Maximilian J. Hochmair,⁶ Gee-Chen Chang,⁷ Angelo Delmonte,⁸ Ki H. Lee,⁹ Rosario G. Campelo,¹⁰ Cesare Gridelli,¹¹ Alexander I. Spira,¹² Raffaele Califano,¹³ Frank Griesinger,¹⁴ Sharmistha Ghosh,¹⁵ Enriqueta Felip,¹⁶ Dong-Wan Kim,¹⁷ Yuyin Liu,¹⁸ Pingkuan Zhang,¹⁹ Sanjay Papat,²⁰ D. Ross Camidge²¹

Abstract

We evaluated brigatinib efficacy and safety compared with crizotinib in an analysis of Asian (n = 108) and non-Asian (n = 167) subgroups from the phase III ALTA-1L study. Brigatinib showed better BIRC-assessed PFS over crizotinib in Asians and non-Asians (HR [95% CI], log-rank: Asians, 0.35 [0.20-0.59], *P* = .0001; non-Asians, 0.56 [0.38-0.84], *P* = .0041). Overall safety was similar between groups.

Background: Brigatinib is a next-generation anaplastic lymphoma kinase (ALK) inhibitor with demonstrated efficacy in locally advanced and metastatic non-small cell lung cancer (NSCLC) in crizotinib-refractory and ALK inhibitor-naive

Abbreviations: AE, adverse event; ALK, anaplastic lymphoma kinase; *ALK*+, anaplastic lymphoma kinase rearrangement-positive; ALT, alanine aminotransferase; ALTA-1L, ALK in Lung Cancer Trial of brigatinib in 1st Line; AST, aspartate aminotransferase; BIRC, blinded independent review committee; BMI, body mass index; CI, confidence interval; CNS, central nervous system; CPK, creatine phosphokinase; CR, complete response; DOR, duration of response; ECOG, Eastern Cooperative Oncology Group; FDA, US Food and Drug Administration; HR, hazard ratio; iPFS, intracranial progression-free survival; NE, not evaluable; NR, not reached; NSCLC, non-small cell lung cancer; OR, odds ratio; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; PK, pharmacokinetic; PR, partial response; RECIST, Response Evaluation Criteria in Solid Tumors; TEAE, treatment-emergent adverse event; TKI, tyrosine kinase inhibitor.

¹Division of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea

²Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea

³Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan, and Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan

⁴Center for Lung Cancer, National Cancer Center, Goyang, South Korea

⁵Department of Clinical Oncology, Hong Kong United Oncology Centre, Kowloon, Hong Kong

⁶Department of Respiratory and Critical Care Medicine, Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Klinik Floridsdorf, Vienna, Austria

⁷School of Medicine, and Institute of Medicine, Chung Shan Medical University, Division of Pulmonary Medicine, Department of Internal Medicine, Chung Shan Medical University Hospital, and Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan

⁸Medical Oncology, Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" (IRST), IRCCS, Meldola, Italy

⁹Department of Internal Medicine, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, South Korea

¹⁰Medical Oncology Department, Thoracic Tumors Unit, Complejo Hospitalario Universitario A Coruña, A Coruña, Spain

¹¹Division of Medical Oncology, A.O.S.G. Moscati, Avellino, Italy

¹²Medical Oncology, Virginia Cancer Specialists and US Oncology Research, Fairfax, VA

¹³Department of Medical Oncology, The Christie NHS Foundation Trust, and Division of Cancer Sciences, The University of Manchester, Manchester, England, UK

¹⁴University Department of Internal Medicine-Oncology, Pius-Hospital Oldenburg, University of Oldenburg, Oldenburg, Germany

¹⁵Department of Medical Oncology, Guy's and St Thomas' NHS Foundation Trust, London, England, UK

¹⁶Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain

¹⁷Department of Internal Medicine, Seoul National University College of Medicine and Seoul National University Hospital, Seoul, Republic of Korea

¹⁸Oncology Statistics, Takeda Development Center Americas, Inc., Lexington, MA

¹⁹Clinical Science, Takeda Development Center Americas, Inc., Lexington, MA

²⁰Lung Unit, The Royal Marsden Hospital and The Institute of Cancer Research, London, England, UK

²¹Department of Medicine, Division of Medical Oncology, University of Colorado Cancer Center, Aurora, CO

Submitted: May 25, 2022; Revised: Jul 8, 2022; Accepted: Jul 16, 2022; Epub: 21 July 2022

Address for correspondence: Myung-Ju Ahn, MD, Division of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwonro Gangnamgu, 06531, Seoul, Korea
E-mail contact: silkahn@skku.edu

settings. This analysis assessed brigatinib in Asian vs. non-Asian patients from the first-line ALTA-1L trial. **Patients and Methods:** This was a subgroup analysis from the phase III ALTA-1L trial of brigatinib vs. crizotinib in ALK inhibitor-naïve ALK+ NSCLC. The primary endpoint was progression-free survival (PFS) as assessed by blinded independent review committee (BIRC). Secondary endpoints included confirmed objective response rate (ORR) and overall survival (OS) in the overall population and BIRC-assessed intracranial ORR and PFS in patients with brain metastases. **Results:** Of the 275 randomized patients, 108 were Asian. Brigatinib showed consistent superiority in BIRC-assessed PFS vs. crizotinib in Asian (hazard ratio [HR]: 0.35 [95% CI: 0.20-0.59]; log-rank $P = .0001$; median 24.0 vs. 11.1 months) and non-Asian (HR: 0.56 [95% CI: 0.38-0.84]; log-rank $P = .0041$; median 24.7 vs. 9.4 months) patients. Results were consistent with investigator-assessed PFS and BIRC-assessed intracranial PFS. Brigatinib was well tolerated. Toxicity profiles and dose modification rates were similar between Asian and non-Asian patients. **Conclusion:** Efficacy with brigatinib was consistently better than with crizotinib in Asian and non-Asian patients with locally advanced or metastatic ALK inhibitor-naïve ALK+ NSCLC. There were no clinically notable differences in overall safety in Asian vs. non-Asian patients.

Clinical Lung Cancer, Vol. 23, No. 8, 720–730 © 2022 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>)

Keywords: ALK TKI-naïve, Anaplastic lymphoma kinase, Clinical trial, First line, Tyrosine kinase inhibitor

Introduction

Anaplastic lymphoma kinase (ALK) receptor tyrosine kinase rearrangements occur in approximately 3% to 5% of patients with non-small cell lung cancer (NSCLC) and occur at similar rates among Asian and non-Asian populations.¹⁻⁴ A number of ALK inhibitors, including crizotinib, alectinib, ceritinib, brigatinib, and lorlatinib, have reported efficacy in treatment of patients with ALK TKI-naïve anaplastic lymphoma kinase-positive (ALK+) NSCLC.⁵⁻¹² Crizotinib, the first approved ALK inhibitor, demonstrated efficacy superior to pemetrexed plus platinum chemotherapy in previously untreated patients.⁶ Studies of the efficacy and safety of crizotinib and of alectinib have demonstrated similar efficacy between Asian and non-Asian patients.^{4,8,13-16}

Brigatinib (ARIAD Pharmaceuticals, Inc., Cambridge, MA) is a next-generation ALK inhibitor that targets a broad range of ALK resistance mutations.¹⁷⁻¹⁹ The phase III ALK in Lung Cancer Trial of brigatinib in 1st Line (ALTA-1L; NCT02737501) trial compared the efficacy and safety of brigatinib and crizotinib in ALK inhibitor-naïve advanced ALK+ NSCLC.⁹⁻¹¹ The primary endpoint, blinded independent review committee (BIRC)-assessed progression-free survival (PFS), was met at the first interim analysis and confirmed at the second interim analysis.^{9,10} At the final analysis, with median follow-up for brigatinib of 40.4 months, brigatinib maintained superiority in BIRC-assessed PFS (hazard ratio [HR]: 0.48 [95% CI: 0.35-0.66]; $P < .0001$), with median PFS of 24.0 months vs. 11.0 months, respectively.¹¹

At the first interim analysis of ALTA-1L, a subgroup analysis in Asian and non-Asian patients reported longer BIRC-assessed PFS with brigatinib compared with crizotinib in both populations (HR for disease progression or death, Asian: 0.41 [95% CI: 0.20-0.86]; non-Asian: 0.54 [95% CI: 0.33-0.90]).⁹ Here, we report final efficacy and safety results of ALTA-1L in Asian and non-Asian patients.

Patients and Methods

ALTA-1L is an open-label, randomized, international, phase III trial. The trial was conducted in accordance with the ethical standards of the Declaration of Helsinki and the International

Council for Harmonization guideline for Good Clinical Practice and was approved by local institutional review boards. All patients provided written informed consent. The detailed methods for this study have been previously published.⁹

Briefly, eligible patients were adults ≥ 18 years of age who had locally advanced or metastatic NSCLC with at least 1 measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1²⁰ and had not previously received ALK-targeted therapy. Patients must have been ALK+ based on locally determined testing. Asymptomatic or stable central nervous system (CNS) metastases were permitted. Patients who had received more than 1 prior systemic anticancer regimen, or radiation therapy within 14 days before the first dose of trial drug, were excluded.

Patients were randomized 1:1 to receive oral brigatinib 180 mg once daily (with 7 days lead-in period at 90 mg once daily) or oral crizotinib 250 mg twice daily in 28 days cycles; they were further stratified according to the presence or absence of brain metastases at baseline and the completion of at least 1 full cycle of chemotherapy for locally advanced or metastatic disease (Yes vs. No). Treatment was continued until disease progression, as assessed by BIRC, unacceptable toxicity, or other discontinuation criteria were met. The intracranial BIRC reviewers were independent from the systemic BIRC reviewers. Crossover from the crizotinib arm to the brigatinib arm was permitted following disease progression, after a 10-day washout period. Brigatinib could be continued after disease progression at the investigator's discretion. Dose interruptions or reductions were permitted for treatment-related adverse events (TEAEs).

The primary endpoint was PFS according to RECIST v1.1 as assessed by the BIRC. Secondary endpoints included the confirmed objective response rate (ORR), confirmed intracranial ORR, intracranial PFS, overall survival (OS), duration of response, and safety. Disease assessments were performed every 8 weeks through cycle 14 and then every 12 weeks until the end of treatment. Responses were confirmed at least 4 weeks after the initial response. Adverse events (AEs) were categorized using the National Cancer Institute Common Terminology Criteria for Adverse Events, v4.03.

Final Results From the Phase III ALTA-1L Study

Table 1 Demographics and Baseline Characteristics

| | Asian | | Non-Asian | |
|--|------------------------|------------------------|------------------------|------------------------|
| | Brigatinib (n = 59) | Crizotinib (n = 49) | Brigatinib (n = 78) | Crizotinib (n = 89) |
| Median age, years (range) | 55 (32-80) | 56 (30-89) | 60 (27-86) | 60 (29-83) |
| Female, n (%) | 31 (53) | 26 (53) | 38 (49) | 55 (62) |
| Median weight, kg (range) ^a | 60 (43-96) | 60 (40-85) | 70 (46-111) | 70 (46-117) |
| Median BMI, kg/m ² (range) ^b | 23 (16-31) | 23 (16-32) | 26 (18-41) | 26 (18-44) |
| ECOG performance status, n (%) | | | | |
| 0 | 18 (31) | 13 (27) | 36 (46) | 40 (45) |
| 1 | 39 (66) | 33 (67) | 37 (47) | 45 (51) |
| 2 | 2 (3) | 3 (6) | 5 (6) | 4 (4) |
| Disease stage at study entry | | | | |
| IIIB | 2 (3) | 5 (10) | 6 (8) | 7 (8) |
| IV | 57 (97) | 44 (90) | 72 (92) | 82 (92) |
| ALK status assessed by locally FDA-approved test, n (%) ^c | 54 (92) | 41 (84) | 69 (88) | 71 (80) |
| Baseline brain metastases, n (%) ^d | 21 (36) | 16 (33) | 19 (24) | 25 (28) |
| Prior radiotherapy to the brain, n (%) | 7 (12) | 8 (16) | 11 (14) | 11 (12) |
| Prior chemotherapy in the locally advanced or metastatic setting, n (%) ^e | 19 (32) | 12 (24) | 17 (22) | 25 (28) |

ALK = anaplastic lymphoma kinase; BMI = body mass index; ECOG = Eastern Cooperative Oncology Group; FDA = Food and Drug Administration; ; FISH, fluorescence in situ hybridization; IHC, immunohistochemistry

^a Asian crizotinib arm, n = 48. Non-Asian arms: brigatinib, n = 77; crizotinib, n = 87

^b Asian crizotinib arm, n = 48. Non-Asian arms: brigatinib, n = 71; crizotinib, n = 82

^c Patients whose ALK+ status was tested locally by Vysis FISH or Ventana IHC

^d As assessed by investigator

^e Prior chemotherapy defined as completion of ≥ 1 full cycle of chemotherapy in the locally advanced or metastatic setting

The final analysis was conducted following the last patient last visit in January, 2020, approximately 3.5 years after last patient first enrollment. This prespecified subgroup analysis of outcomes in Asian vs. non-Asian patients was conducted following the final analysis. Asian patients included all patients whose race was self-reported as native Asian. Efficacy was evaluated in the intention-to-treat population, in Asian and non-Asian patients separately. PFS was compared between the 2 arms using a 2-sided stratified log-rank test (stratification factors: presence of intracranial CNS metastases at baseline [Yes vs. No], and prior chemotherapy for locally advanced or metastatic disease [Yes vs. No]); ethnicity was not a stratification parameter. Median time to efficacy events and 95% CIs were estimated for each treatment arm using the Kaplan-Meier method. The safety population included all patients who received at least 1 dose of study drug. Statistical analyses were performed using Base 9.4 SAS/STAT 13.1 software (SAS Institute, Cary, NC). Data are reported as of the data cutoff date for the final analysis of January 29, 2021.¹¹

Results

Patients

A total of 275 patients were randomized, with 108 (39%) Asian patients and 167 (61%) non-Asian patients. The median age, weight, and body mass index of Asian patients were slightly less than those of non-Asian patients (Table 1). Numerically more Asian patients had Eastern Cooperative Oncology Group performance status 1 compared with the non-Asian population (Table 1). There were no other substantial differences between populations


or between brigatinib- and crizotinib-treated patients. At study completion, no patient in either arm remained on treatment. Median follow-up was similar between the Asian and non-Asian cohorts; 40.7 months (range 0.7-49.9 months) and 39.8 months (range 0-52.4 months) in the brigatinib arm, respectively, and 13.6 months (range 0.1-47.0 months) and 15.5 months (range 0.3-51.7 months), respectively, in the crizotinib arm.

Efficacy

Systemic Progression-free Survival. Consistent with results from the overall population, brigatinib demonstrated better BIRC-assessed PFS over crizotinib in both Asian and non-Asian patients. In Asian patients, the HR for PFS was 0.35 [95% CI: 0.20-0.59]; $P = .0001$ by log-rank test; Figure 1A). In non-Asian patients, the HR was 0.56 [95% CI: 0.38-0.84]; $P = .0041$ by log-rank test; Figure 1B). Investigator-assessed PFS supports BIRC assessment, continuing to show improvements with brigatinib in Asian and in non-Asian patients vs. crizotinib (Figure 1C, D).


Systemic Response Rate and Duration of Response. Among Asian patients, the BIRC-assessed confirmed ORR (n/N; 95% CI) was 80% (47/59; 67%-89%) in the brigatinib arm and 71% (35/49; 57%-83%) in the crizotinib arm (Table 2). In non-Asian patients, confirmed ORR was 71% (55/78; 59%-80%) with brigatinib and 57% (51/89; 46%-68%) with crizotinib. Disease control rates were similar across treatment groups in Asian and non-Asian patients. The duration of response among confirmed responders was longer with brigatinib treatment, with a median duration of 22.2 months

Figure 1 Efficacy of brigatinib and crizotinib in Asian and non-Asian patients with TKI-naive *ALK+* NSCLC. Kaplan-Meier–estimated BIRC-assessed PFS for (A) Asian and (B) non-Asian patients in the intention-to-treat population; Kaplan-Meier–estimated investigator-assessed PFS for (C) Asian and (D) non-Asian patients in the intention-to-treat population; overall survival for (E) Asian and (F) non-Asian patients in the intention-to-treat population.




ALK = anaplastic lymphoma kinase gene; BIRC = blinded independent review committee; CI = confidence interval; HR = hazard ratio; NR = not reached; NSCLC = non-small cell lung cancer; OS = overall survival; PFS = progression-free survival; TKI = tyrosine kinase inhibitor.


Figure 1 Continued



| Number at risk | 0 | 6 | 12 | 18 | 24 | 30 | 36 | 42 | 48 |
|----------------|----|----|----|----|----|----|----|----|----|
| Brigatinib | 78 | 57 | 48 | 43 | 40 | 35 | 30 | 17 | 2 |
| Crizotinib | 89 | 49 | 31 | 24 | 15 | 13 | 12 | 6 | 1 |



| Number at risk | 0 | 6 | 12 | 18 | 24 | 30 | 36 | 42 | 48 |
|----------------|----|----|----|----|----|----|----|----|----|
| Brigatinib | 59 | 52 | 47 | 43 | 40 | 39 | 38 | 22 | 3 |
| Crizotinib | 49 | 45 | 42 | 38 | 33 | 32 | 30 | 12 | 1 |



| Number at risk | 0 | 6 | 12 | 18 | 24 | 30 | 36 | 42 | 48 |
|----------------|----|----|----|----|----|----|----|----|----|
| Brigatinib | 78 | 69 | 61 | 54 | 52 | 49 | 46 | 30 | 4 |
| Crizotinib | 89 | 78 | 74 | 68 | 61 | 58 | 54 | 30 | 4 |

Table 2 BIRC-Assessed Objective Response Rate (Intent-to-treat Population)

| | Asian | | | Non-Asian | | |
|--|--------------------|--------------------|---|--------------------|---------------------|--|
| | Brigatinib | Crizotinib | OR (95% CI) ^a | Brigatinib | Crizotinib | OR (95% CI) ^a |
| Intention-to-treat population | | | | | | |
| No. of patients | 59 | 49 | | 78 | 89 | |
| Confirmed ORR, n (%) (95% CI) | 47 (80) (67-89) | 35 (71) (57-83) | 1.70 (0.69-4.18); <i>P</i> = .2546 | 55 (71) (59-80) | 51 (57) (46-68) | 1.77 (0.93-3.36); <i>P</i> = .0783 |
| Disease control rate, n (%) (95% CI) | 53 (90) (79-96) | 45 (92) (80-98) | | 64 (82) (72-90) | 74 (83) (74-90) | |
| Median DOR in confirmed responders, months (95% CI) | 22.2 (16.6-NE) | 11.0 (9.1-19.3) | | 41.4 (22.2-NE) | 19.4 (11.1-35.8) | |
| Probability of maintaining response, % (95% CI) | | | | | | |
| 1 year | 76 (61-86) | 46 (28-63) | | 79 (66-88) | 63 (47-75) | |
| 2 years | 48 (33-62) | 25 (11-41) | | 60 (45-72) | 42 (27-56) | |
| 3 years | 46 (31-60) | 14 (4-29) | | 52 (37-64) | 33 (19-48) | |
| Patients with any brain metastases at baseline (as assessed by the BIRC ^b) | | | | | | |
| No. of patients | 21 | 18 | | 26 | 31 | |
| Confirmed intracranial ORR, % (95% CI) | 13 (62) (38-82) | 6 (33) (13-59) | 7.24 (1.22-42.87); <i>P</i> = .0212 | 18 (69) (48-86) | 1 (3) (0-17) | 71 (6.86-734.32); <i>P</i> < .0001 |
| Intracranial CR, n (%) | 11 (52) | 0 | | 10 (38) | 1 (3) | |
| Intracranial PR, n (%) | 2 (10) | 6 (33) | | 8 (31) | 0 | |

BIRC = blinded independent review committee; CI = confidence interval; CR = complete response; DOR = duration of response; NE = not evaluable; NR = not reached; OR = odds ratio; ORR = objective response rate; PR = partial response

^a ORs (brigatinib vs. crizotinib) and *P* values are from a Cochran-Mantel-Haenszel test stratified by presence of brain metastases at baseline and prior chemotherapy for locally advanced or metastatic disease

^b Intracranial reviewers were independent from systemic reviewers

and 11.0 months among Asian patients treated with brigatinib and crizotinib, respectively. Median duration of response was 41.4 months for brigatinib compared with 19.4 months in the crizotinib group in the non-Asian group (Table 2).

Overall Survival. A total of 92 patients died as of the data cutoff date (January 29, 2021). In both the Asian and non-Asian subgroups, more patients died in the crizotinib arm (Asian patients: brigatinib, 13 [22%]; crizotinib, 14 [29%]; non-Asian patients: brigatinib, 28 [36%]; crizotinib, 37 [42%]). OS trended in favor of brigatinib in both the Asian and non-Asian populations (HR for OS, Asian patients: 0.71 [95% CI: 0.33-1.53]; *P* = .4063 by log-rank test (Figure 1E); non-Asian patients: 0.89 [95% CI: 0.54-1.46]; *P* = .6800 by log-rank test (Figure 1F).


Efficacy in Patients With Brain Metastases. A total of 96 patients had baseline brain metastases as assessed by BIRC (Asian patients: brigatinib, 21, crizotinib, 18; non-Asian patients: brigatinib, 26, crizotinib, 31). There was a better intracranial ORR in both Asian and non-Asian patients treated with brigatinib than with crizotinib. Confirmed intracranial ORR (n/N; 95% CI) in Asian patients was 62% (13/21; 38%-82%) for brigatinib and 33% (6/18; 13%-59%) for crizotinib (odds ratio [OR] for brigatinib vs. crizotinib, 7.24

[95% CI: 1.22-42.87]; *P* = .0212; Table 2). In non-Asian patients, confirmed intracranial ORR was 69% (18/26; 48%-86%) for brigatinib and 3% (1/31; 0%-17%) for crizotinib (OR: 71.00 [95% CI: 6.86-734.32]; *P* < .0001). Among all patients, regardless of whether brain metastases were present at baseline, BIRC-assessed intracranial PFS was better in patients treated with brigatinib vs. crizotinib (Figure 2A, 2B).


Safety

Brigatinib was well tolerated in both Asian and non-Asian populations (Table 3). The most common (> 25% of patients overall) any-grade TEAEs were gastrointestinal events, increased blood creatine phosphokinase, cough, increased aminotransferases, and peripheral edema. There were no remarkable differences in AE profiles between the Asian and non-Asian populations. The incidence of increased aspartate aminotransferase (31% vs. 22%), increased alanine aminotransferase (31% vs. 17%), and constipation (25% vs. 16%) was numerically higher in Asian patients treated with brigatinib than in non-Asian patients. Diarrhea (64% vs. 51%), nausea (40% vs. 24%), and peripheral edema (13% vs. 5%) were more frequent in non-Asian patients treated with brigatinib than in Asian patients treated with brigatinib.

Figure 2 Intracranial efficacy of brigatinib and crizotinib in (A) Asian and (B) non-Asian patients with TKI-naive *ALK*+ NSCLC regardless of brain metastases at baseline. Kaplan-Meier–estimated BIRC-assessed PFS for the intention-to-treat population. Intracranial reviewers were independent from systemic reviewers.¹¹



| Number at risk | | 0 | 6 | 12 | 18 | 24 | 30 | 36 | 42 | 48 | 54 |
|----------------|----|----|----|----|----|----|----|----|----|----|----|
| Brigatinib | 59 | 44 | 40 | 33 | 25 | 23 | 21 | 11 | 0 | | |
| Crizotinib | 49 | 30 | 14 | 11 | 8 | 6 | 5 | 1 | 0 | | |



| Number at risk | | 0 | 6 | 12 | 18 | 24 | 30 | 36 | 42 | 48 | 54 |
|----------------|----|----|----|----|----|----|----|----|----|----|----|
| Brigatinib | 78 | 59 | 49 | 43 | 41 | 36 | 30 | 20 | 2 | | |
| Crizotinib | 89 | 46 | 31 | 26 | 18 | 13 | 12 | 8 | 2 | | |

ALK = anaplastic lymphoma kinase gene; BIRC = blinded independent review committee; CI = confidence interval; HR = hazard ratio; iPFS = intracranial progression-free survival; NR = not reached; NSCLC = non-small cell lung cancer; PFS = progression-free survival; TKI = tyrosine kinase inhibitor.

Table 3 Safety Overview and Treatment-Emergent Adverse Events^a of Any Grade Reported in $\geq 25\%$ of All Patients (Safety Population)

| | Asian | | | | Non-Asian | | | |
|---|---------------------|----------------|---------------------|----------------|---------------------|----------------|---------------------|----------------|
| | Brigatinib (n = 59) | | Crizotinib (n = 48) | | Brigatinib (n = 77) | | Crizotinib (n = 89) | |
| | Any | Grade ≥ 3 | Any | Grade ≥ 3 | Any | Grade ≥ 3 | Any | Grade ≥ 3 |
| Overview of adverse events, n (%) | | | | | | | | |
| Any adverse event | 59 (100) | 42 (71) | 48 (100) | 25 (52) | 77 (100) | 53 (69) | 89 (100) | 52 (58) |
| Adverse event leading to dose reduction | 27 (46) | – | 9 (19) | – | 33 (43) | – | 25 (28) | – |
| Adverse event leading to treatment interruption | 43 (73) | – | 21 (44) | – | 55 (71) | – | 44 (49) | – |
| Adverse event leading to treatment discontinuation | 5 (8) | – | 3 (6) | – | 13 (17) | – | 9 (10) | – |
| Adverse events reported in $\geq 25\%$ of all patients, n (%) | | | | | | | | |
| Diarrhea | 30 (51) | 1 (2) | 23 (48) | 0 | 49 (64) | 2 (3) | 54 (61) | 4 (4) |
| Increased blood CPK | 30 (51) | 20 (34) | 7 (15) | 1 (2) | 38 (49) | 16 (21) | 16 (18) | 1 (1) |
| Cough | 22 (37) | 0 | 6 (13) | 0 | 27 (35) | 0 | 23 (26) | 0 |
| Increased AST | 18 (31) | 4 (7) | 17 (35) | 1 (2) | 17 (22) | 2 (3) | 19 (21) | 8 (9) |
| Increased ALT | 18 (31) | 4 (7) | 21 (44) | 3 (6) | 13 (17) | 2 (3) | 28 (31) | 11 (12) |
| Constipation | 15 (25) | 0 | 16 (33) | 0 | 12 (16) | 1 (1) | 41 (46) | 0 |
| Nausea | 14 (24) | 0 | 27 (56) | 2 (4) | 31 (40) | 3 (4) | 54 (61) | 2 (2) |
| Vomiting | 11 (19) | 0 | 20 (42) | 1 (2) | 19 (25) | 2 (3) | 41 (46) | 2 (2) |
| Peripheral edema | 3 (5) | 0 | 19 (40) | 0 | 10 (13) | 1 (1) | 44 (49) | 1 (1) |

AE = adverse event; ALT = alanine aminotransferase; AST = aspartate aminotransferase; CPK = creatine phosphokinase

^a AEs starting or worsening on or after the first dose of study treatment and no later than the earliest of (1) 30 days after the last dose of treatment to which the patient was assigned, or (2) the day before the start of brigatinib therapy in patients who crossed over

^b Patients treated with ≥ 1 dose of study medication

tinib. It is notable that this trend of slight differences in AE frequency was also generally observed in patients treated with crizotinib.

Grade ≥ 3 TEAEs occurred at similar rates in Asian (71%) vs. non-Asian patients (69%) treated with brigatinib. More Asian than non-Asian patients treated with brigatinib experienced grade ≥ 3 increases in creatinine phosphokinase (34% vs. 21%). In this study, disease progression was required to be reported as an AE unless it was asymptomatic radiological progression alone. Twenty-two patients had AEs leading to death, most attributed to lung cancer progression. None were deemed related to study treatment by the investigator. Among Asian patients, interstitial lung disease/pneumonitis at any time occurred in 7% of patients (4/59) in the brigatinib arm and no patients in the crizotinib arm, with grade 3 or 4 interstitial lung disease occurring in 3% of patients (2/59) treated with brigatinib. Any-grade interstitial lung disease/pneumonitis with early onset (defined as within 14 days of treatment initiation) was observed in 3% of patients (2/59) in the brigatinib arm. Among non-Asian patients, interstitial lung disease/pneumonitis at any time was reported in 5% of patients (4/77) in the brigatinib arm, similar to that in Asian patients, and 3% of patients (3/89) in the crizotinib arm. Grade 3 or 4 pneumonitis occurred in 3% of patients (2/77) treated with brigatinib and 1% of patients (1/89) treated with crizotinib. Any-grade early-onset pneumonitis was reported in 3% of patients (2/77) treated with brigatinib; no early-onset interstitial lung disease was reported in non-Asian patients.

The dose modification rate was similar between both populations treated with brigatinib (Table 3). Median brigatinib dose intensity

was 150.0 mg/d for Asian patients and 165.6 mg/d for non-Asian patients. In the crizotinib arm, the median dose intensity was 496.9 mg/d and 494.5 mg/day for Asian and non-Asian patients, respectively. Dose reduction due to AEs was mandated by investigator or protocol in 46% and 19% of Asian patients in the brigatinib and crizotinib arms, respectively, and in 43% and 28% of non-Asian patients, respectively. Fewer Asian patients (brigatinib, 8%; crizotinib, 6%) than non-Asian patients (brigatinib, 17%; crizotinib, 10%) discontinued treatment due to TEAEs. There was no remarkable difference in the profile of AEs that led to drug discontinuation in Asian vs. non-Asian patients.

Discussion

Results from a phase I ethnobridging study (data on file) demonstrated a lack of race effects on the pharmacokinetic (PK) profile of brigatinib in healthy Asian and white volunteers. These results were supported by a population PK model-based analysis of patients in ALTA-1L that showed consistent brigatinib systemic exposures in Asian and non-Asian patients.²¹

In this ALTA-1L final analysis, brigatinib showed sustained improvement in systemic and intracranial efficacy compared with crizotinib in both Asian and non-Asian patients with ALK inhibitor-naïve *ALK+* NSCLC, consistent with the analyses of the overall population^{9-11,22} and with the report based on the first interim analysis.⁹ Asian patients show a trend of better PFS with brigatinib over crizotinib than non-Asian patients; however, the HRs had overlapping 95% CIs and the median PFS was similar for both treatment arms in Asian and Non-Asian populations. One limitation of our analysis is that the Cox proportional regression

Final Results From the Phase III ALTA-1L Study

analysis did not account for covariates other than the 2 stratification factors, which have slightly, but not significantly, different distributions in the Asian and non-Asian populations. To avoid any potential impact from these 2 randomization factors, they were included in the regression model for adjustment. The median PFS is a point estimate of survival, while HR describes the overall distribution. The Kaplan-Meier curves show that the separation in BIRC-assessed PFS between brigatinib and crizotinib is more obvious in Asians than in non-Asians without considering the impact of any covariate and can explain the lower HR in the Asian population.

Previous studies have demonstrated similar efficacy between Asian and non-Asian patients treated with crizotinib and alectinib.^{4,8,13-15} In an analysis of previously treated (1 prior platinum-based regimen) and untreated patients from PROFILE 1007 and 1014, comparable benefits were observed in Asian and non-Asian patients.⁴ In Asian patients, the HR for PFS was 0.53 (95% CI: 0.36-0.76; $P < .001$; median PFS: crizotinib 8.1 months, chemotherapy 2.8 months); in non-Asian patients, the HR for PFS was 0.45 (95% CI: 0.30-0.66; $P < .001$; median PFS: crizotinib 7.1 months vs. chemotherapy 3.2 months).⁴ In the ALEX study comparing alectinib and crizotinib in patients with TKI-naïve NSCLC, PFS subgroup analyses showed similar benefit in Asian (HR: 0.46 [95% CI: 0.280-0.75]) and non-Asian (HR: 0.49 [95% CI: 0.32-0.75]) patients.^{8,15} With longer follow-up of ALTA-1L, this study strengthens the observation that second-generation ALK TKIs improve PFS and intracranial efficacy compared with crizotinib in patients with advanced *ALK+* NSCLC, regardless of ethnicity.

In ALTA-1L, Asian patients had a trend toward better survival in both arms compared with non-Asian patients, with numerically higher 3-year OS rates for both brigatinib and crizotinib. In subgroup analyses of Asian and non-Asian patients from the PROFILE 1014 trial of crizotinib vs. chemotherapy, the HR (95% CI) for OS was 0.93 (0.58-1.49) in Asian patients and 0.72 (0.47-1.11) in non-Asians.¹⁶ In the ALEX trial of alectinib vs. crizotinib, the HR for OS was 0.74 (0.40-1.36) for Asians and 0.69 (0.43-1.10) for non-Asians.¹⁵

The safety profile of brigatinib in Asian and non-Asian patients was consistent with the established safety profile of brigatinib from multiple studies.^{11,19,23} Brigatinib was well tolerated in both Asian and non-Asian patients, reflected by similar rates of dose modifications between the 2 subpopulations. Certain toxicities, such as nausea and vomiting, were more frequent in the non-Asian population in both treatment arms. A similar finding was observed for alectinib in a subgroup analysis of the ALEX study.²⁴ The underlying reason is unknown and may be related to dietary habits or reporting bias. With longer follow-up, the pneumonitis rate did not significantly differ in Asian vs. non-Asian patients who received brigatinib.

Conclusion

Results from the final analysis of the ALTA-1L trial demonstrate brigatinib to be better in terms of efficacy compared with crizotinib in both Asian and non-Asian patients. Brigatinib is well tolerated and represents a once-daily, single-tablet, promising first-line treatment option in both Asian and non-Asian patients with ALK inhibitor-naïve locally advanced or metastatic *ALK+* NSCLC.

Clinical Practice Points

- Brigatinib is a second-generation ALK TKI approved for treatment of advanced *ALK+* NSCLC. In the phase III ALTA-1L trial, brigatinib demonstrated superior efficacy vs. crizotinib in patients with ALK TKI-naïve *ALK+* NSCLC and was well tolerated. We conducted a planned analysis in Asian and non-Asian subgroups from ALTA-1L to determine the effects of ethnicity on efficacy and tolerability of brigatinib.
- Consistent with overall ALTA-1L results, brigatinib demonstrated consistently better BIRC-assessed PFS compared with crizotinib in both Asian and non-Asian patients (HR, Asian: 0.35 [95% CI: 0.20-0.59], $P = .0001$; HR, non-Asian: 0.56 [0.38-0.84], $P = .0041$). Patients in the brigatinib arm also had numerically better overall ORR (OR [Asian/non-Asian]: 1.70/1.77), intracranial ORR (OR: 7.24/71.00), and trend to longer OS (HR: 0.71/0.89) vs. crizotinib. Brigatinib was well tolerated in both groups. Higher percentages of increased creatinine phosphokinase, aspartate aminotransferase, alanine aminotransferase, and constipation reported in Asian patients were not clinically meaningful, and dose modification rates were similar between Asian and non-Asian patients.
- These results are supported by a phase I PK study in healthy Asian and white volunteers that demonstrated a lack of race effects on the brigatinib PK profile (data on file). A population PK model-based analysis of patients in ALTA-1L also showed comparable systemic exposures to brigatinib in Asian and non-Asian patients.
- This subgroup analysis from long-term follow-up demonstrates the consistent efficacy and tolerability of brigatinib in Asian and non-Asian patients. Brigatinib represents a first-line treatment option in Asian patients with ALK inhibitor-naïve advanced *ALK+* NSCLC.

Author Contributions

Conceptualization: M.J. Ahn, M.J. Hochmair, P. Zhang, S. Popat, D.R. Camidge

Data curation (*Management activities to annotate [produce metadata], scrub data and maintain research data [including software code, where it is necessary for interpreting the data itself] for initial use and later reuse*): G.C. Chang, A.I. Spira, F. Griesinger, Y. Liu, P. Zhang, S. Popat

Formal analysis: M.J. Hochmair, A.I. Spira, F. Griesinger, Y. Liu, P. Zhang

Funding acquisition: A.I. Spira, P. Zhang

Investigation: M.J. Ahn, H.R. Kim, J.C.H. Yang, J.Y. Han, J.Y.C. Li, M.J. Hochmair, G.C. Chang, A. Delmonte, K.H. Lee, M.R. García Campelo, C. Gridelli, A.I. Spira, R. Califano, F. Griesinger, S. Ghosh, E. Felip, D.W. Kim, P. Zhang, S. Popat, D.R. Camidge

Methodology: M.J. Hochmair, A.I. Spira, Y. Liu, P. Zhang, S. Popat, D.R. Camidge

Project administration (*Management and coordination responsibility for the research activity planning and execution*): M.J. Hochmair, G.C. Chang, A.I. Spira, R. Califano, P. Zhang, S. Popat, D.R. Camidge

Resources (*Provision of study materials, reagents, materials, patients, laboratory samples, animals, instrumentation, computing resources, or other analysis tools*): M.J. Ahn, H.R. Kim, J.C.H. Yang, J.Y.

Han, J.Y.C. Li, M.J. Hochmair, G.C. Chang, A. Delmonte, K.H. Lee, M.R. García Campelo, C. Gridelli, A. Spira, R. Califano, F. Griesinger, S. Ghosh, E. Felip, D.W. Kim, P. Zhang, S. Popat, D.R. Camidge

Software (*Programming, software development; designing computer programs; implementation of the computer code and supporting algorithms; testing of existing code components*): M.J. Hochmair

Supervision (*Oversight and leadership responsibility for the research activity planning and execution, including mentorship external to the core team*): A.I. Spira, F. Griesinger, P. Zhang, S. Popat, D.R. Camidge

Validation (*Verification, whether as a part of the activity or separate, of the overall replication/reproducibility of results/experiments and other research outputs*): M.J. Ahn, M.J. Hochmair, G.C. Chang, M.R. García Campelo, A.I. Spira, R. Califano, F. Griesinger, E. Felip, Y. Liu, P. Zhang, S. Popat, D.R. Camidge

Visualization (*Preparation, creation and/or presentation of the published work, specifically visualization/data presentation*): M.J. Ahn, M.J. Hochmair, M.R. García Campelo, A.I. Spira, P. Zhang, S. Popat, D.R. Camidge

Writing - review & editing: All authors

Data Sharing Statement

The data sets, including the redacted study protocol, redacted statistical analysis plan, and individual participant data supporting the results reported in this article, will be made available within 3 months from initial request, to researchers who provide a methodologically sound proposal. The data will be provided after de-identification, in compliance with applicable privacy laws, data protection, and requirements for consent and anonymization.

ClinicalTrials.gov registration

NCT02737501

Acknowledgments

The authors would like to thank the patients, their families, and their caregivers; the ALTA-1L investigators and their team members at each study site; and colleagues from Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. Professional medical writing assistance was provided by Lauren Gallagher, RPh, PhD, of Peloton Advantage, LLC, an OPEN Health company, Parsippany, NJ, USA, and funded by Millennium Pharmaceuticals, Inc. Teodor G. Paunescu, PhD (Takeda Pharmaceuticals U.S.A., Inc.) is acknowledged for editorial assistance.

This study was supported by ARIAD Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. The sponsor designed and conducted the study and collected the data together with the authors. The sponsor managed and analyzed the data. Data were interpreted by the authors and the sponsor. The sponsor together with the authors prepared, reviewed, and approved the manuscript and made the decision to submit the manuscript for publication.

Disclosure

M. J. Ahn: Honoraria (AstraZeneca, Merck Sharp & Dohme, Roche, Bristol Myers Squibb, Merck KGaA, Alpha Pharmaceuticals)

outside of the submitted work. H. R. Kim: Honoraria (Bristol Myers Squibb, AstraZeneca, Merck Sharp & Dohme, Takeda) outside of the submitted work. J. C. H. Yang: Honoraria or advisory role (Boehringer Ingelheim, Eli Lilly, Bayer, Roche/Genentech/Chugai, Astellas, Merck Sharp & Dohme, Merck Serono, Pfizer, Novartis, Celgene, Merrimack, Yuhan Pharmaceuticals, BMS, Ono Pharmaceutical, Daiichi Sankyo, Takeda, AstraZeneca, Hansoh Pharmaceuticals). J. Y. Han: Research grants (Hoffmann-La Roche Ltd, Ono, Pfizer, Takeda); consulting/advisor fees (AstraZeneca, Bristol Myers Squibb, Eli Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Takeda, MedPacto, Abion, Ono); honoraria (AstraZeneca, Bristol Myers Squibb, Hoffmann-La Roche Ltd., Merck Sharp & Dohme, Takeda). M. J. Hochmair: Honoraria (AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Merck Sharp & Dohme, Pfizer, Takeda, Roche); consulting or advisory role (Boehringer Ingelheim, Merck Sharp & Dohme, Pfizer, Novartis, Takeda, Roche). G. C. Chang: Honoraria (F. Hoffmann-La Roche, Ltd, Eli Lilly and Company Oncology, AstraZeneca, Novartis, Pfizer, Boehringer Ingelheim, Bristol Myers Squibb, Merck Sharp & Dohme). A. Delmonte: Consulting/advisory role (AstraZeneca, Boehringer Ingelheim). K. H. Lee: Support of clinical research (Merck), honoraria for advisory board participation (AstraZeneca, Bristol Myers Squibb, Lilly, Merck Sharp & Dohme, Pfizer, Yu-han). M. R. García Campelo: Consulting/advisory role (Merck Sharp & Dohme, Bristol Myers Squibb, Roche, Boehringer Ingelheim, Pfizer, Novartis, AstraZeneca, Lilly, Takeda, Bayer, Sanofi, Janssen); speakers bureau (Merck Sharp & Dohme, Bristol Myers Squibb, Roche, Boehringer Ingelheim, Pfizer, Novartis, AstraZeneca, Lilly, Takeda, Janssen). C. Gridelli: Honoraria as advisory board member or speaker bureau member (AstraZeneca, Roche, Pfizer, Eli Lilly, Merck Sharp & Dohme, Bristol Myers Squibb, Novartis); honoraria as consultant (Menarini, Roche). A. Spira: Consulting/advisory role (ARIAD, AstraZeneca, Clovis Oncology, Roche, Amgen, Mirati, Bristol Myers Squibb, Merck). R. Califano: Honoraria and consulting or advisory role (AstraZeneca, Bristol Myers Squibb, Roche, Merck Sharp & Dohme, Boehringer Ingelheim, Takeda, Novartis). F. Griesinger: Support of scientific research (AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Takeda, Siemens, Amgen, GlaxoSmithKline, Janssen); honoraria for presentations (AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Takeda, ARIAD, AbbVie, Siemens, Amgen, GlaxoSmithKline, Janssen, Sanofi); advisory board participation (AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Takeda, ARIAD, AbbVie, Siemens, GlaxoSmithKline, Janssen, Sanofi). E. Felip: Personal fees (AbbVie, Amgen, AstraZeneca, Bayer, BeiGene, Blue Print Medicines, Boehringer Ingelheim, Bristol Myers Squibb, CME Outfitters, Eli Lilly, GlaxoSmithKline, Janssen, Medical Trends, Medscape, Merck KGaA, Merck Sharp & Dohme, Novartis, PeerVoice, Peptomyc, Pfizer, Prime Oncology, Puma Biotechnology, Regeneron, Roche, Sanofi Genzyme, Springer, Takeda, Touch Medical); grants (Grant for Oncology Innovation [GOI], Fundación Merck Salud); advisory board (Syneos Health); independent member of the board

Final Results From the Phase III ALTA-1L Study

(Griffols). D. W. Kim: Research funding (all to institution: Alpha Biopharma, Amgen, AstraZeneca/Medimmune, Boehringer Ingelheim, Daiichi Sankyo, Hanmi, Janssen, Merus, Mirati Therapeutics, Merck Sharp & Dohme, Novartis, Ono Pharmaceutical, Pfizer, Roche/Genentech, Takeda, TP Therapeutics, Xcovery, Yuhan, Chong Kun Dang, Bridge BioTherapeutics, GlaxoSmithKline); travel/accommodation support for advisory board meeting attendance (Amgen, Daiichi-Sankyo). Y. Liu: Employment (Takeda). P. Zhang: Employment (Takeda). S. Popat: NHS funding to the National Institute for Health Research Biomedical Research Centre at the Royal Marsden Hospital/Institute of Cancer Research; honoraria (Boehringer Ingelheim, AstraZeneca, Roche, Takeda, Novartis, Bristol Myers Squibb, Merck Sharp & Dohme, Merck KGaA, Bayer, Blueprint Medicines, Daiichi Sankyo, Guardant Health, Janssen, GlaxoSmithKline, BeiGene, Incyte, Lilly, Amgen); consulting or advisory role (Boehringer Ingelheim, Roche, Novartis, Pfizer, AstraZeneca, Bristol Myers Squibb, Merck Sharp & Dohme, Guardant Health, Takeda, Incyte, Bayer, Blueprint Medicines, Daiichi Sankyo, Janssen, GlaxoSmithKline, BeiGene, Lilly, Merck KGaA, Amgen); research funding (Mirati Therapeutics, Trizell; to institution: Boehringer Ingelheim, Epizyme, Bristol Myers Squibb, Clovis Oncology, Roche; Lilly, Takeda, Celgene, Novartis, ARIAD, Merck Sharp & Dohme, Daiichi Sankyo, Guardant Health, Janssen, GlaxoSmithKline, Turning Point Therapeutics); travel/accommodations/expenses (Boehringer Ingelheim, Merck Sharp & Dohme, Roche). D. R. Camidge: Advisory/consulting role (AbbVie, Apollomics [SRC], AstraZeneca [SRC/SC], Daiichi-Sankyo [ILD adjudication committee], Elevation [SRC], Kestrel [SAB], Nuvalent [SAB], Seattle Genetics, Takeda, Turning Point, Amgen, Anchiano [SAB], BioThera [DSMB], Bristol Myers Squibb, Eisai, EMD Serono, Eli Lilly, GlaxoSmithKline, Helsinn, Janssen, OnKure, Mersana, Pfizer, Qilu, Roche, Sanofi, CBT Pharmaceuticals, G1 Therapeutics [DSMB], Blueprint, Achilles, BeyondSpring, 14ner/Elevation [SRC], Archer, Medtronic, Ribon); research funding (Inivata); PI roles (AbbVie, AstraZeneca, Dizal, Inhibrx, Karyopharm, Pfizer, Phosphatin, PsiOxus, Rain, Roche/Genentech, Seattle Genetics, Takeda, Turning Point). All remaining authors have declared no conflicts of interest.

REFERENCES

- Gainor JF, Varghese AM, Ou SH, et al. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. *Clin Cancer Res*. 2013;19:4273–4281. doi:10.1158/1078-0432.Ccr-13-0318.
- Koivunen JP, Mermel C, Zejnullahu K, et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. *Clin Cancer Res*. 2008;14:4275–4283. doi:10.1158/1078-0432.Ccr-08-0168.
- Wong DW, Leung EL, So KK, et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. *Cancer*. 2009;115:1723–1733. doi:10.1002/cncr.24181.
- Nishio M, Kim DW, Wu YL, et al. Crizotinib versus chemotherapy in Asian patients with ALK-positive advanced non-small cell lung cancer. *Cancer Res Treat*. 2018;50:691–700. doi:10.4143/crt.2017.280.
- Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. *N Engl J Med*. 2013;368:2385–2394. doi:10.1056/NEJMoa1214886.
- Solomon BJ, Mok T, Kim DW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. *N Engl J Med*. 2014;371:2167–2177. doi:10.1056/NEJMoa1408440.
- Soria JC, Tan DS, Chiari R, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. *Lancet*. 2017;389:917–929. doi:10.1016/s0140-6736(17)30123-x.
- Peters S, Camidge DR, Shaw AT, et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. *N Engl J Med*. 2017;377:829–838. doi:10.1056/NEJMoa1704795.
- Camidge DR, Kim HR, Ahn MJ, et al. Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer. *N Engl J Med*. 2018;379:2027–2039. doi:10.1056/NEJMoa1810171.
- Camidge R, Kim HR, Ahn M, et al. Brigatinib versus crizotinib in advanced ALK inhibitor-naïve ALK-positive non-small cell lung cancer: Second interim analysis of the phase III ALTA-1L trial. *J Clin Oncol*. 2020;38:3592–3603. doi:10.1200/JCO.20.00505.
- Camidge DR, Kim HR, Ahn M-J, et al. Brigatinib versus crizotinib in ALK inhibitor-naïve advanced ALK-positive NSCLC: Final results of phase 3 ALTA-1L trial. *J Thorac Oncol*. 2021;16:2091–2108. doi:10.1016/j.jtho.2021.07.035.
- Shaw AT, Bauer TM, de Marinis F, et al. First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. *N Engl J Med*. 2020;383:2018–2029. doi:10.1056/NEJMoa2027187.
- Wu YL, Lu S, Lu Y, et al. Results of PROFILE 1029, a phase III comparison of first-line crizotinib versus chemotherapy in east asian patients with ALK-positive advanced non-small cell lung cancer. *J Thorac Oncol*. 2018;13:1539–1548. doi:10.1016/j.jtho.2018.06.012.
- Zhou C, Kim SW, Reungwetwattana T, et al. Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study. *Lancet Respir Med*. 2019;7:437–446. doi:10.1016/s2213-2600(19)30053-0.
- Mok T, Camidge DR, Gadgeel SM, et al. Updated overall survival and final progression-free survival data for patients with treatment-naïve advanced ALK-positive non-small-cell lung cancer in the ALEX study. *Ann Oncol*. 2020;31:1056–1064. doi:10.1016/j.annonc.2020.04.478.
- Solomon BJ, Kim DW, Wu YL, et al. Final overall survival analysis from a study comparing first-line crizotinib versus chemotherapy in ALK-mutation-positive non-small-cell lung cancer. *J Clin Oncol*. 2018;36:2251–2258. doi:10.1200/jco.2017.77.4794.
- Katayama R, Khan TM, Benes C, et al. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. *Proc Natl Acad Sci USA*. 2011;108:7535–7540. doi:10.1073/pnas.1019559108.
- Huang WS, Liu S, Zou D, et al. Discovery of brigatinib (AP26113), a phosphine oxide-containing, potent, orally active inhibitor of anaplastic lymphoma kinase. *J Med Chem*. 2016;59:4948–4964. doi:10.1021/acs.jmedchem.6b00306.
- Gettinger SN, Bazhenova LA, Langer CJ, et al. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: A single-arm, open-label, phase 1/2 trial. *Lancet Oncol*. 2016;17:1683–1696.
- Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). *Eur J Cancer*. 2009;45:228–247. doi:10.1016/j.ejca.2008.10.026.
- Gupta N, Reckamp KL, Camidge DR, et al. Population pharmacokinetic and exposure-response analyses from ALTA-1L: model-based analyses supporting the brigatinib dose in ALK-positive NSCLC. *Clin Transl Sci*. 2022;15:1143–1154. doi:10.1111/cts.13231.
- Ahn MJ, Kim H, Chih-Hsin Yang J, et al. Brigatinib (BRG) versus crizotinib (CRZ) in Asian versus non-Asian patients (pts) in the phase III ALTA-1L trial [abstract]. *J Clin Oncol*. 2019;37:9026. doi:10.1200/JCO.2019.37.15_suppl.9026.
- Huber RM, Hansen KH, Paz Ares Rodríguez L, et al. Brigatinib in crizotinib-refractory ALK+ NSCLC: 2-year follow-up on systemic and intracranial outcomes in the phase 2 ALTA trial. *J Thorac Oncol*. 2020;15:404–415. doi:10.1016/j.jtho.2019.11.004.
- Mok TSK, Peters S, Camidge DR, et al. Alectinib (ALC) vs. crizotinib (CRZ) in treatment-naïve ALK+ non-small-cell lung cancer (NSCLC): Asian vs. non-Asian subgroup analysis of the ALEX study [abstract 4100_PR]. *Ann Oncol*. 2017;28(suppl 10):x191. doi:10.1093/annonc/mdx729.009.